Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Medi
October 03, 2016
Allergan shows it has stomach for more GI dealmaking
July 19, 2016
Celgene pays through the nose for a hand in immune checkpoints
May 03, 2016
Regeneron nips at Amgen and Pfizer’s heels in pain drug race
December 22, 2015
Therapy focus – How do you solve a problem like CAR-T relapse?
April 24, 2015
Celgene signals bigger immuno-oncology push into blood cancers
March 24, 2015
Tanezumab’s return shows pharma has held its nerve
June 19, 2014
Astra makes quiet progress with respiratory pipeline
May 12, 2014
Astra’s brodalumab hit is perfectly timed
May 07, 2014
Don’t blame Soriot, he’s just doing his job
January 14, 2014
Merck catches Bristol with surprise PD-1 filing
November 07, 2013
Lilly deal hints at renewed interest in once promising pain class
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
August 15, 2022
Q2 Roundp Medtech Infographic
August 12, 2022
Q2 Roundup Pharma Infographic
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
